MERCK BIOVENTURES
Why India needs to back a new R&D treaty in health sectorLess than 10% of the $160 bn R&D spend is devoted to 90% of the world’s disease burden. India suffers, yet it is not being vocal for a glob...- Biosimilar products development gets a USFDA norms boostA biosimilar is a product that is similar to a biologic, which in turn is any drug produced through a biological route rather than chemical...
- Load More